182 Chapter 7 90. Dave, J. et al. Gene editing reverses arrhythmia susceptibility in humanized PLN-R14del mice: modeling a European cardiomyopathy with global impact. Cardiovasc. Res. (2022) doi:10.1093/cvr/cvac021. 91. Monda, E. et al. Clinical and Molecular Characteristics of Patients with PLN R14del Cardiomyopathy: State-ofthe-Art Review. Cardiogenetics vol. 12 112–121 Preprint at https://doi.org/10.3390/cardiogenetics12010012 (2022). 92. Eijgenraam, T. R. et al. Antisense Therapy Attenuates Phospholamban p.(Arg14del) Cardiomyopathy in Mice and Reverses Protein Aggregation. Int. J. Mol. Sci. 23, (2022). 93. Deiman, F. E., Bomer, N., van der Meer, P. & Grote Beverborg, N. Review: Precision Medicine Approaches for Genetic Cardiomyopathy: Targeting Phospholamban R14del. Curr. Heart Fail. Rep. (2022) doi:10.1007/s11897022-00558-x. 94. Vera, C. D. et al. Generation of two induced pluripotent stem cell lines carrying the phospholamban R14del mutation for modeling ARVD/C. Stem Cell Res. 63, 102834 (2022). 95. Harakalova, M. et al. Transcriptional regulation profiling reveals PPARA-mediated fatty acid oxidation as a novel therapeutic target in phospholamban R14del cardiomyopathy. (2022) doi:10.21203/rs.3.rs-1902254/v1. 96. Vafiadaki, E., Haghighi, K., Arvanitis, D. A., Kranias, E. G. & Sanoudou, D. Aberrant PLN-R14del Protein Interactions Intensify SERCA2a Inhibition, Driving Impaired Ca Handling and Arrhythmogenesis. Int. J. Mol. Sci. 23, (2022). 97. Rogalska, M. E. et al. Isoform changes of action potential regulators in the ventricles of arrhythmogenic phospholamban-R14del humanized mouse hearts. Metabolism 138, 155344 (2023). 98. Aboumsallem, J. P. et al. Multi-omics analyses identify molecular signatures with prognostic values in different heart failure aetiologies. J. Mol. Cell. Cardiol. 175, 13–28 (2023). 99. Kumar, M. et al. Myofilament Alterations Associated with Human R14del-Phospholamban Cardiomyopathy. Int. J. Mol. Sci. 24, (2023). 100. Vafiadaki, E., Glijnis, P. C., Doevendans, P. A., Kranias, E. G. & Sanoudou, D. Phospholamban R14del disease: The past, the present and the future. Front Cardiovasc Med 10, 1162205 (2023). 101. Cleary, S. R. et al. Dilated cardiomyopathy variant R14del increases phospholamban pentamer stability, blunting dynamic regulation of cardiac calcium handling. bioRxiv : the preprint server for biology (2023) doi:10.1101/2023.05.26.542463. 102. de Brouwer, R. et al. A randomized controlled trial of eplerenone in asymptomatic phospholamban p.Arg14del carriers. Eur. Heart J. 44, 4284–4287 (2023). 103. Maniezzi, C. et al. Early consequences of the phospholamban mutation PLN-R14del+/- in a transgenic mouse model. bioRxiv 2023.04.05.535536 (2023) doi:10.1101/2023.04.05.535536. 104. Doevendans, P. A. Should we offer preventive treatment to all carriers of PLN p.(Arg14del) variant? Neth. Heart J. 31, 289–290 (2023). 105. Boer, D. & Rudolf, A. Should we offer preventive treatment to all carriers of PLN p.(Arg14del) variant? Neth. Heart J. 31, 287–288 (2023). 106. Taha, K. et al. Deep neural network-based clustering of deformation curves reveals novel disease features in PLN pathogenic variant carriers. Int. J. Cardiovasc. Imaging 39, 2149–2161 (2023). 107. Balducci, V. et al. Generation and characterization of novel human induced pluripotent stem cell (iPSC) lines originating from five asymptomatic individuals carrying the PLN-R14del pathogenic variant and a non-carrier relative. Stem Cell Res. 72, 103208 (2023). 108. Stege, N. M. et al. DWORF Extends Life Span in a PLN-R14del Cardiomyopathy Mouse Model by Reducing Abnormal Sarcoplasmic Reticulum Clusters. Circ. Res. 133, 1006–1021 (2023). 109. van der Voorn, S. M. et al. Lack of Evidence for the Role of the p.(Ser96Ala) Polymorphism in Histidine-Rich Calcium Binding Protein as a Secondary Hit in Cardiomyopathies. Int. J. Mol. Sci. 24, (2023). 110. MacLennan, D. H. & Kranias, E. G. Phospholamban: a crucial regulator of cardiac contractility. Nat. Rev. Mol. Cell Biol. 4, 566–577 (2003). 111. van der Zwaag, P. A. et al. Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur. J. Heart Fail. 14, 1199–1207 (2012).
RkJQdWJsaXNoZXIy MTk4NDMw